Trials Sponsors Conditions Drugs Pricing

Conditions

non-segmental vitiligo

Outcome Measures

Primary Outcomes (1)

Proportion of subjects achieving VASI-50 (defined as at least 50% improvement in VASI from baseline) at Week 32. - Percent change from baseline in VASI, facial-VASI, vitiligo extent score (VES), and self-assessment VES (SA-VES) and absolute change from baseline in VASI at designated time points - Change from baseline in vitiligo specific quality of life (VitiQoL) and dermatology quality life index (DLQI) at designated time points.

Interventions

Pioglitazone Morningside 15mg TabletsType not reported

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
Pioglitazone Morningside 15mg Tablets
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry record

Ingredients named in source formulations

The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.

Pioglitazone Morningside 15mg Tablets
Named ingredient: Pioglitazone
View registry record

Eligibility Criteria

Sexall

Age GroupsAdult (18-64)

You may qualify if:

Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study; • Adults between 18 Years and 65 Years of all genders; • Female subjects of childbearing potential and at risk for pregnancy must agree to use one method of contraception throughout the study and for at least 30 days after the last dose of assigned treatment; Female subjects of non-childbearing potential must meet at least 1 of the following criteria: a. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state; b. Have undergone a documented hysterectomy and/or bilateral oophorectomy; c. Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered childbearing potential. Has a clinical diagnosis of non-segmental vitiligo for at least 6 months BSA ≥0.5% involvement on the face at screening and baseline (confirmed by photographs);

Sponsors & Collaborators

I.F.O. Istituti Fisioterapici Ospitalieri
Type not reportedlead

Study Sites (2)

I.F.O. Istituti Fisioterapici Ospitalieri

Rome, 00144, Italy

Barbara Bellei00390652666246 barbara.bellei@ifo.it

Fondazione Luigi Maria Monti

Rome, 00167, Italy

Mauro Michele Picardo00390666464721 m.picardo@idi.it

Central Study Contacts

Massimo Zeuli

00390652666237 massimo.zeuli@ifo.it

Study Design

Study Type: interventional
Phase: phase 2

Study Record Dates

First Submitted

June 20, 2024

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2024-515642-17-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-30 05:24:00 UTC

Documents

Protocol 2024_515642_17_00

You may not qualify if:

Unable to consent (adults lacking capacity); • Partecipants that have diagnosis of other type of vitiligo including segmental and mixed vitiligo; • Has ≥50% leukotrichia on face or body; • Unable to return for follow-up visits; • Pregnant women and/or breastfeeding, or those who have recently delivered a baby within the past 6 months; • Has any other dermatological diseases that would interfere with vitiligo assessments; • History of type I or II diabetes • Has a transplanted organ, which requires continued immunosuppression; • Systemic immunosuppressive medication (oral corticosteroids) within prior 4 weeks; • Currently undergoing UVB light therapy or history of light therapy within the past 8 weeks; • Has a history of any malignancy, except for localized in situ skin carcinoma; • Has had major surgery within 3 months prior to Screening OR has a major surgery planned during the study; • Prior/Concurrent investigational clinical study experience; • Enrolled in a clinical study of any other investigational drug or device; • Diabetes, liver disease, or kidney disease; • Hypoglycemia as defined by fasting blood glucose <70 mg/dL assessed at a fasting study visit; • ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: • Absolute neutrophil count of <2.5 x 109/L (<2500/mm3); • Hemoglobin <10.0 g/dL or hematocrit <30%; • Platelet count below the lower limit of normal (LLN) at Screening; • Absolute lymphocyte count of <0.8 x 109 /L (<800/mm3); • Serum creatinine > upper limit of normal (ULN) or eGFR <60 ml/min/1.73m2 based on the age appropriate calculation. • Enzymes aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >2 times the ULN; • Total bilirubin 1.5 times the ULN; subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ULN; • Creatine kinase (CK) >3 times the ULN and positive urine myoglobin; • In the opinion of the investigator, have any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject’s participation in the study. • In the investigator's judgment, any concomitant diseases or therapies that might interfere with the reliability of the study analyses.

A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations